Cadazolid Does Not Promote Intestinal Colonization of Vancomycin-Resistant Enterococci in Mice.
The promotion of colonization with vancomycin-resistant enterococci (VRE) is one potential side effect during treatment of Clostridium difficile-associated diarrhea (CDAD), resulting from disturbances in gut microbiota. Cadazolid (CDZ) is an investigational antibiotic with potent in vitro activity against C. difficile and against VRE and is currently in clinical development for the treatment of CDAD. We report that CDZ treatment did not lead to intestinal VRE overgrowth in mice.
Actelion Pharmaceuticals Ltd., Allschwil, Switzerland peter.seiler@actelion.com.
Peter
P
Seiler
Actelion Pharmaceuticals Ltd., Allschwil, Switzerland.
Michel
M
Enderlin-Paput
Actelion Pharmaceuticals Ltd., Allschwil, Switzerland.
Philippe
P
Pfaff
Actelion Pharmaceuticals Ltd., Allschwil, Switzerland.
Maria
M
Weiss
Actelion Pharmaceuticals Ltd., Allschwil, Switzerland.
Daniel
D
Ritz
Actelion Pharmaceuticals Ltd., Allschwil, Switzerland.
Martine
M
Clozel
Actelion Pharmaceuticals Ltd., Allschwil, Switzerland.
Hans H
HH
Locher
D000617:Aminoglycosides / Q000494:pharmacology; D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000009:adverse effects*; D016360:Clostridioides difficile / Q000187:drug effects* / Q000254:growth & development / Q000472:pathogenicity; D015169:Colony Count, Microbial; D003967:Diarrhea / Q000188:drug therapy* / Q000209:etiology / Q000382:microbiology / Q000473:pathology; D004761:Enterocolitis, Pseudomembranous / Q000188:drug therapy* / Q000209:etiology / Q000382:microbiology / Q000473:pathology; D000077732:Fidaxomicin; D007422:Intestines / Q000187:drug effects / Q000382:microbiology / Q000473:pathology; D008795:Metronidazole / Q000494:pharmacology; D051379:Mice; D008826:Microbial Sensitivity Tests; D023303:Oxazolidinones / Q000494:pharmacology*; D013290:Streptococcal Infections / Q000188:drug therapy / Q000382:microbiology / Q000473:pathology; D016896:Treatment Outcome; D014640:Vancomycin / Q000008:administration & dosage / Q000009:adverse effects*; D020713:Vancomycin Resistance; D065507:Vancomycin-Resistant Enterococci / Q000187:drug effects / Q000254:growth & development / Q000472:pathogenicity
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D023303:Oxazolidinones; D008795:Metronidazole; C000591679:cadazolid; D014640:Vancomycin; D000077732:Fidaxomicin